Hong Kong Stock Exchange Exploration | Healthy World Technology-B: LuX-Valve Plus TRAVEL II one-year clinical follow-up results to be released at the 2024 American Washington Congress of Cardiology through the catheter.

CH Energy Eng (03996) controlling shareholder received financial support for shareholding in A shares; following Takeda's FRUQUINTINIB (呋喹替尼/fruquintinib) sales exceeding 0.2 billion US dollars, Hutchmed (China) (00013) will receive the first milestone payment.

Zhitong FinanceOct 31 11:07 ET

Express News | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical - Received Acceptance Notice by Nmpa for Abbreviated New Drug Application for Obeticholic Acid Tablets

ReutersOct 31 04:54 ET

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. (688505.SH): Obei cholic acid tablets for the treatment of primary biliary cholangitis pharmaceutical marketing application has been accepted.

On October 31, Bio-Thera Solutions (688505.SH) announced that its wholly-owned subsidiary, Taizhou Bio-Thera Solutions Pharmaceutical Co., Ltd., recently received the "Acceptance Notification" from the National Medical Products Administration regarding the application for domestic production pharmaceutical registration and market approval of obeticholic acid tablets (specifications: 5mg, 10mg) (referred to as "the drug") for the treatment of primary biliary cholangitis (PBC). This drug is a farnesoid X receptor (FXR) agonist, with FXR being a nuclear receptor highly expressed in the liver and intestines.

Gelonghui FinanceOct 31 04:40 ET

Fudan Zhangjiang Third Quarter Report 2024

SZSIOct 25 12:00 ET · Announcements

Fudan-Zhangjiang Bio-Pharma's Q3 Profit Slides 25%

MT NewswiresOct 25 06:16 ET

shanghai fudan-zhangjiang bio-pharmaceutical co. ltd. (01349.HK): net income attributable to equity holders of the parent company in the first three quarters was 86.4686 million yuan

Gelonghui October 25th | Shanghai Fudan-Zhangjiang Bio-pharmaceutical Co. Ltd. (01349.HK) announced that in the third quarter of 2024, revenue was 0.141 billion RMB, a decrease of 23.99% year-on-year; net income attributable to shareholders of the listed company was 15.9955 million RMB, a decrease of 25.44% year-on-year; net income attributable to shareholders of the listed company excluding non-recurring gains and losses was 10.8224 million RMB, a decrease of 34.74% year-on-year; earnings per share was 0.02 RMB. In the first three quarters of 2024, revenue was 0.549 billion RMB, a decrease of 22.47% year-on-year.

Gelonghui FinanceOct 25 05:46 ET